BIRAC

More in BIRAC

• SII’s Cervavac- India’s approved indigenous HPV vaccine to cost Rs 200-400

  The scientific completion of the qHPV vaccine is a moment of pride for us, and India, at large. The indigenously developed vaccine will make our country self-sufficient in curbing female mortality caused by cervical cancer. We would like to thank DBT and BIRAC for supporting us in achieving this significant milestone: Adar Poonawalla

  • Exclusive

  

• Dr. Moopen’s Medical College gets BIRAC funding

  BioNEST is a dedicated scheme supported by the BIRAC to create globally competent bioincubation facilities to undertake strategic research and innovation.

  

• Fibroheal raises debt funding from BIRAC

  The company intends to scale up its go to market capabilities, recruit more people onboard and create an impact through the economic multiplier potential of silk protein and healing different types of acute, chronic, non healing, slow healing, difficult to heal wounds including post operative wounds

  

• ZyCov-D is the 6th Approved COVID-19 Vaccine and 2nd to be indigenously developed : Mandaviya

  World’s first Plasmid DNA Vaccine ZyCoV-D administered in three doses can be administered to the age group of 12-18 years in India.

  

• Gennova to get Rs 100 crore from govt for Covid-19 vaccine

  A total of Rs 900 crore has been earmarked for Covid-19 vaccine development to be implemented by BIRAC (Biotechnology Industry Research Assistance Council) under the Department of Biotechnology. Last year, over six vaccine candidates under development by domestic drug companies including Zydus Cadila and Gennova, were provided seed funds for around Rs 15-20 crore each.

  

• Nasscom, BIRAC launch contest to develop health tech solution for small towns, rural areas

  IT industry body Nasscom and state-run Biotechnology Industry Research Assistance Council (BIRAC) on Monday launched a contest, JANCare, to develop technology solutions for the delivery of health care solutions in small towns and rural areas.

  

• Zydus Cadila to apply for Phase-3 trials in December, hopes to launch vaccine by March

  The Ahmedabad-based drug maker will submit the results of its phase-2 trials next week, which "will ascertain the safety, dose and efficacy of the potential vaccine", said the person who requested not to be identified.

  

• Dr Reddy's joins hands with BIRAC for Sputnik V clinical trials

  The company said the partnership will enable it to identify and use some of BIRAC’s clinical trial centres for the vaccine, which are funded under the National Biopharma Mission (NBM), implemented by Project Management Unit-NBM at BIRAC.

  

• Aurobindo ties up with Biotechnology Industry Research Assistance Council for COVID-19 vaccine

  Aurobindo Pharma said it is developing a vaccine for COVID-19 through its wholly-owned US subsidiary, Auro Vaccines. The vaccine candidate is based on a proprietary vaccine delivery platform of the company.

  

• Pan-India 1000 genome sequencing of SARS-CoV-2 completed: Dr Harsh Vardhan

  According to an official release, the Department of Biotechnology had launched a Pan-India 1000 SARS--CoV-2 RNA Genome Sequencing programme in May this year to be done by Autonomous Institutes of DBT, collaborating with national laboratories and clinical organisations.

  

• India to play key role in determining whether world achieves SDGs: Mundel

  Mundel said India has 1 million 'missing cases'of tuberculosis (TB) and has the opportunity of developing improved solutions for TB case finding and reporting, and treatment adherence.